|
KR20190062332A
|
|
Method for preparation of biological active polypeptide conjugate
|
|
KR20180019634A
|
|
Method for preparation of biological active polypeptide conjugate
|
|
KR20170005179A
|
|
Method for preparation of biological active polypeptide conjugate
|
|
US2017020991A1
|
|
Insulin conjugate using an immunoglobulin fragment
|
|
AU2014202057A1
|
|
Novel Fused Pyrimidine Derivatives for Inhibition of Tyrosine Kinase Activity
|
|
KR20150008282A
|
|
Method, apparatus and server for providing information sharing service
|
|
US2015118255A1
|
|
Liquid formulation of highly concentrated long-acting human growth hormone conjugate
|
|
EP2825633A1
|
|
Method of culturing e. coli cells for high density
|
|
AR090281A1
|
|
IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
|
|
SG11201401205UA
|
|
Blood coagulation factor ? and ?a derivatives, conjugates and complexes comprising the same, and use thereof
|
|
KR20120139579A
|
|
A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
|
|
NZ755534A
|
|
Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
|
|
NZ727090A
|
|
Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
|
|
SG195192A1
|
|
Non-peptidyl polymer-insulin multimer and method for producing the same
|
|
NZ618793A
|
|
Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate
|
|
KR20120110163A
|
|
Fixed dose combination drug composition comprising losartan, amlodipine and hydrochlorothiazide
|
|
KR20130103190A
|
|
Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
|
|
KR20130078634A
|
|
A site-specific glp-2 conjugate using an immunoglobulin fragment
|
|
KR20130078633A
|
|
Derivatives of immunglobulin fc fragment
|
|
KR20130049671A
|
|
Method for preparation of biological active polypeptide conjugate
|
